Eli Lilly’s Retatrutide Yields 28.3% Weight Loss, Boosts 2026 Guidance to $82–$85B
LLY•Eli Lilly’s Retatrutide Phase 3 data showed an average 28.3% body weight reduction over 80 weeks at the 12 mg dose, with one-third of patients reaching healthy weight and two-thirds falling below obesity. The company raised its full-year 2026 revenue forecast to $82–$85 billion after Q1 revenue jumped 56% to $19.8 billion.
1. Retatrutide Phase 3 Results
In the Phase 3 trial, participants on the 12 mg dose of retatrutide achieved an average 28.3% body weight reduction (approximately 70 pounds) over 80 weeks, with one-third reaching a healthy weight and two-thirds falling below the obesity threshold. The 4 mg dose delivered a 19% reduction with a 4% discontinuation rate, and a 104-week extension showed an average 85-pound loss (30.3%) in high-risk patients.
2. Financial Impact and Guidance Revision
Following the trial results, shares rose 4.4% in premarket trading, contributing to a year-to-date gain of over 5% and a 30% increase since Q1 earnings. First-quarter revenue climbed 56% to $19.8 billion, prompting a full-year 2026 forecast raise to $82–$85 billion ahead of a potential FDA submission by year-end.
3. Foundayo Menopause Analysis
A combined analysis of more than 1,500 women in ATTAIN 1 and ATTAIN 2 studies showed Foundayo induced 12.8%–14.4% weight loss over 72 weeks across menopausal stages, equating to approximately 28–30 pounds. Additionally, 80%–83% of women lost at least 5% of body weight, 41%–52% lost at least 15%, and waist circumference decreased by up to 4.9 inches.
